Skip to main content

Pediatric Rheum

Keys to Mastery (5.2.2025)

Dr. Jack Cush reviews the news, articles and drug approvals from the past week on RheumNow.com. This podcast marks the beginning of our Lupus Campaign called "Lupus Unlocked: Keys to Mastery". This month's campaign on Lupus is sponsored by Aurinia.

Read Article
Procalcitonin > 0.9 ng/mL can be a critical marker for identifying bacterial infection in #SLE. Single center study of 116 juv. SLE pts dx bacterial infx in 17%. Procalcitonin was signif better than others: NLR, PLR, ESR, CRP, LC4R, ferritin (cut offs need to be defined) https://t.co/3ujTDIucFM
Dr. John Cush @RheumNow( View Tweet )
Neglected adult PFAPA syndrome case ub 69 yoF mis-Dx as pharyngitis or lymphadenitis unresponsive to Abx. Could've been Rx w/ daily colchicine. (PFAPA = Periodic Fever, Aphthous stomatitis, Pharyngitis and cervical Adenitis) https://t.co/0Nx5uFlwSx https://t.co/ZAUILEsH8E
Dr. John Cush @RheumNow( View Tweet )

2024 Management of Familial Mediterranean Fever Recommendations

A EULAR/PReS combined task force has developed recommendations for the management of Familial Mediterranean fever (FMF), the most common monogenic autoinflammatory disease worldwide. These evidence-based recommendations update the 2016 recommendations developed for rheumatologists and other HCPs

Read Article
Unmet Needs in Still’s disease In February 2023, an expert consensus panel of pediatric and adult rheumatologists met to address challenges in Still’s disease (SD), including systemic juvenile idiopathic arthritis (sJIA) and adult-onset SD (AOSD). They addressed four main https://t.co/h6FNkQyoKj
Dr. John Cush @RheumNow( View Tweet )

Rheumatology: Believe It or Not (4/25/2025)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Should we believe the reviews and metanalyses?

Read Article
Retrospective study of 334 children with non-organic amplified MSK pain syndr(AMPS) plus back pain. Pts w/ localized AMPS were more likely to have a (+) straight leg raising test (P 0.01) & diffuse AMPS more likely to have allodynia & incongruent affect (reporting pain, but still https://t.co/unbub6VK0t
Dr. John Cush @RheumNow( View Tweet )

Unmet Needs in Still’s disease

In February 2023, an expert consensus panel of pediatric and adult rheumatologists met to address challenges in Still’s disease (SD), including systemic juvenile idiopathic arthritis and adult-onset SD. They addressed four main topics: (1) early recognition and diagnosis of SD; (2) pathogenetic

Read Article

2025 BSR Guideline for Treatment of Axial Spondyloarthritis

The British Society of Rheumatology has published its 2025 Guidelines for the Treatment of Axial Spondyloarthritis (axSpA); addressing axial and extra-musculoskeletal manifestations including acute anterior uveitis, psoriasis and IBD.  They address the effectiveness and safety of

Read Article
If you see women with inflammatory arthritis who are pregnant or planning a pregnancy, the MAMA Study may be recruiting at an obstetric unit near you. To find out what is happening, visit @TheMAMAStudy, https://t.co/N8B5MpTsRx, or email mama@npeu.ox.ac.uk. @NPEU_CTU @NPEU_Oxford https://t.co/lQdgUiZ0Cb
Is High Dose Aspirin Needed in Kawasaki Disease (KD)? Does aspirin add any advantage to intravenous immunoglobulin (IVIG) alone in children with KD? A randomized clinical trial IVIG alone was not inferior to IVIG plus aspirin, suggesting that high-dose aspirin during initial https://t.co/vThkP4AH6x
Dr. John Cush @RheumNow( View Tweet )

Is High Dose Aspirin Needed in Kawasaki Disease?

Does aspirin add any advantage to intravenous immunoglobulin (IVIG) alone in children with Kawasaki disease (KD)? A randomized clinical trial IVIG alone was not inferior to IVIG plus aspirin, suggesting that high-dose aspirin during initial IVIG treatment did not reduce coronary artery

Read Article
Uveitis Risk with Slow Adalimumab Weaning Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort analysis indicated. https://t.co/KgQsK6fVnr
Dr. John Cush @RheumNow( View Tweet )
📢Calling all paediatrics! #BSR25 is almost here - Check out our top paediatric highlights from a packed Annual Conference programme 🔗Read our latest blog now: https://t.co/8uJMiqg2fW https://t.co/PAASNk3ZuF
Prof Ian Giles will be covering a range of topics at this year's Rheumapreg Conference such as how immunologic changes and placental dysfunction cause adverse outcomes in rheumatic disease pregnancies. View the full prgramme and learn more: https://t.co/tjiycjKJ8i https://t.co/FugHvtm8fY

EMR Messaging Woes (4.11.2025)

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com

Read Article
185 children with SLE (cSLE) were analyze for long-term outcomes. 38 (20.54%) had serositis. Pts w/ serositis were younger, had more Dz activity, acomorbidities, & mortality. Having both serositis and ESRD increased risk of poor 20 Yr survival. https://t.co/fw8wcuS48E https://t.co/LgS3Sxy7gd
Dr. John Cush @RheumNow( View Tweet )
185 children with SLE (cSLE) were analyze for long-term outcomes. 38 (20.54%) had serositis. Pts w/ serositis were younger, had more Dz activity, acomorbidities, & mortality. Having both serositis and ESRD increased risk of poor 20 Yr survival. https://t.co/tnYgg6MNXp https://t.co/zJor1oTFfD
Dr. John Cush @RheumNow( View Tweet )

Uveitis Risk with Slow Adalimumab Weaning

MedPage Today

Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort analysis indicated.

Read Article
🎉 Today's Annual Scientific Conference kicked off with The CARRA Registry Retreat! The retreat brought together physician-PIs, research coordinators, research managers and patients/caregivers involved with the CARRA Registry. 💙 #CARRA2025 #pedsrheum https://t.co/GYYHAjsIdK

1st Line Biologics vs csDMARDs in Adult Still's Disease

A German multicentre, retrospective study assessed the first-line efficacy of biologics and conventional synthetic DMARD therapy in patients with adult-onset Still's disease and found biologic agents were significantly better with sustained, event-free remissions and fewer complications.

Read Article

Worse Outcomes in HLA-B27+ JIA

MedPage Today

Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marker tended to have worse long-term outcomes, including lower rates of drug-free remission, in a prospective Scandinavian study.

Read Article

Autoimmune Disease Impact Report

Integrated Benefit Institute, a nonprofit independent research organization, has published its 2025 Autoimmune Disease Impact Report, which examines the health and productivity impacts of five prevalent and costly autoimmune conditions: rheumatoid arthritis, multiple sclerosis,

Read Article

Targeting Obesity in Rheumatic Disease Patients

Sattar et al. has published an informative overview of the effect of obesity on rheumatic and musculoskeletal diseases (RMDs). They estimate that nearly 70% of RMD patients are overweight or obese.

Read Article

ERA, APPs, & Alpha GAL (3.21.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  Listen in for 2 new case questions - Ask Cush Anything.

Read Article
×